SSStephanie L. Smith-Roe

Stephanie L. Smith-Roe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Stephanie L. Smith-Roe has a total of 115 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Evaluation of 2,2’-Dimorpholinodiethyl Ether (DMDEE) in Pathology, Perinatal, and Genotoxicity Studies

    by Rachel Frawley, Stephanie L. Smith-Roe, Helen Cunny, Michelle C. Cora, Karr Stinson, Guanhua Xie, Suramya Waidyanatha, Barry McIntyre, Karen Cimon

  • Open Access

    Benzo[ b ]fluoranthene Induces Mutation Accumulation and Cancer‐Relevant Mutational Signatures in Mouse Lung Alongside Steady State Levels of Chromosome Damage in Blood

    by Xinwen Zhang, Cheryl A. Hobbs, Miriam V. Rivas, Alex Diesing, Danielle P. M. LeBlanc, Gu Zhou, Julie F. Foley, Paul A. White, Francesco Marchetti, Carole L. Yauk, et al.

    Polycyclic aromatic hydrocarbons (PAHs) are well‐known for their mutagenic and carcinogenic effects. Benzo[ b ]fluoranthene (BbF) is one of 16 PAHs prioritized by the US Environmental Protection Agency for toxicological evaluation due to pervasive human exposure. As part of a multi‐stakeholder consortium, the genotoxic effects of BbF were evaluated in MutaMouse males exposed to five doses of BbF or a vehicle control via repeated oral gavage for 28, 60, 90, 120, or 180 days, with dose ranges adjusted by duration of exposure. Mutagenesis was evaluated in lung tissue ( n = 4) at 28, 90, and 180 days using Duplex Sequencing (DS), and chromosomal damage ( n = 8) was evaluated using the micronucleus assay in peripheral blood at all time points. Dose‐ and time‐dependent increases in total mutation frequency (MF) and C:G > A:T mutations were observed in lung tissue after 28, 90, and 180 days of exposure. By 28 days, BbF exposure produced lung cancer‐associated mutational signatures linked to tobacco smoking. Mutations accumulated over time in lung, whereas chromosomal damage in peripheral blood erythrocytes reached a steady state by 28 days. Benchmark dose (BMD) confidence intervals (CIs) narrowed with extended exposure only for MF. Collectively, the data demonstrate that BbF is a potent mutagen capable of inducing cancer‐relevant mutations in lung, supporting its potential role in human lung carcinogenesis. By distinguishing early mutagenic responses from cumulative mutation effects over time, these findings highlight the value of integrating mutagenicity assessment into extended‐duration studies to better inform the potential health effects of chronic genotoxic exposures.

  • Open Access

    Application of error-corrected sequencing technologies for in vivo regulatory mutagenicity assessment

    by Carole L. Yauk, Anthony M. Lynch, Vasily N. Dobrovolsky, Maik Schuler, Stephanie L. Smith-Roe, Devon Fitzgerald, Jake Higgins, Naveed Honarvar, Frank Le Curieux, Shoji Matsumura, et al.


  • Open Access

    Dose-related Mutagenic and Clastogenic Effects of Benzo[b]fluoranthene in Mouse Somatic Tissues Detected by Duplex Sequencing and the Micronucleus Assay

    by D. M. Schuster, D. P. M. LeBlanc, G. Zhou, M. J. Meier, A. E. Dodge, P. A. White, A. S. Long, A. Williams, C. Hobbs, A. Diesing, et al.

    Polycyclic aromatic hydrocarbons (PAHs) are common environmental pollutants that originate from the incomplete combustion of organic materials. We investigated the clastogenicity and mutagenicity of benzo[ b ]fluoranthene (BbF), one of 16 priority PAHs, in MutaMouse males after a 28-day oral exposure. BbF causes robust dose-dependent increases in micronucleus frequency in peripheral blood, indicative of chromosome damage. Duplex Sequencing (DS), an error-corrected sequencing technology, reveals that BbF induces dose-dependent increases in mutation frequencies in bone marrow (BM) and liver. Mutagenicity is increased in intergenic relative to genic regions, suggesting a role for transcription-coupled repair of BbF-induced DNA damage. At higher doses, the maximum mutagenic response to BbF is higher in liver, which has a lower mitotic index but higher metabolic capacity than BM; however, mutagenic potency is comparable between the two tissues. BbF induces primarily C:G>A:T mutations, followed by C:G>T:A and C:G>G:C, indicating that BbF metabolites mainly target guanines and cytosines. The mutation spectrum of BbF correlates with cancer mutational signatures associated with tobacco exposure, supporting its contribution to the carcinogenicity of combustion-derived PAHs in humans. Overall, BbF’s mutagenic effects are similar to benzo[ a ]pyrene, a well-studied mutagenic PAH. Our work showcases the utility of DS for effective mutagenicity assessment of environmental pollutants. Synopsis: We used Duplex Sequencing to study the mutagenicity of benzo[ b ]fluoranthene across the mouse genome. Dose-dependent changes in mutation frequency and spectrum quantify its role in PAH-induced carcinogenicity.


  • Open Access

    Adopting duplex sequencing technology for genetic toxicity testing: A proof-of-concept mutagenesis experiment with N-ethyl-N-nitrosourea (ENU)-exposed rats

    by Stephanie L. Smith-Roe, Cheryl A. Hobbs, Victoria Hull, J. Todd Auman, Leslie Recio, Michael A. Streicker, Miriam V. Rivas, Gabriel A. Pratt, Fang Yin Lo, Jacob E. Higgins, et al.


  • Open Access

    Error-corrected duplex sequencing enables direct detection and quantification of mutations in human TK6 cells with strong inter-laboratory consistency

    by Eunnara Cho, Carol D. Swartz, Andrew Williams, Miriam V. Rivas, Leslie Recio, Kristine L. Witt, Elizabeth K. Schmidt, Jeffry Yaplee, Thomas H. Smith, Phu Van, et al.


  • Open Access

    Adopting Duplex Sequencing™ Technology for Genetic Toxicity Testing: A Proof-of-Concept Mutagenesis Experiment with N-Ethyl-N-Nitrosourea (ENU)-Exposed Rats

    by Stephanie L. Smith-Roe, Cheryl A. Hobbs, Victoria Hull, J. Todd Auman, Leslie Recio, Michael A. Streicker, Miriam V. Rivas, Gabriel A. Pratt, Fang Yin Lo, Jacob E. Higgins, et al.

    Duplex sequencing (DuplexSeq) is an error-corrected next-generation sequencing (ecNGS) method in which molecular barcodes informatically link PCR-copies back to their source DNA strands, enabling computational removal of errors by comparing grouped strand sequencing reads. The resulting background of less than one artifactual mutation per 10 7 nucleotides allows for direct detection of somatic mutations. TwinStrand Biosciences, Inc. has developed a DuplexSeq-based mutagenesis assay to sample the rat genome, which can be applied to genetic toxicity testing. To evaluate this assay for early detection of mutagenesis, a time-course study was conducted using male Hsd:Sprague Dawley SD rats (3 per group) administered a single dose of 40 mg/kg N-ethyl-N-nitrosourea (ENU) via gavage, with mutation frequency (MF) and spectrum analyzed in stomach, bone marrow, blood, and liver tissues at 3 h, 24 h, 7 d, and 28 d post-exposure. Significant increases in MF were observed in ENU-exposed rats as early as 24 h for stomach (site of contact) and bone marrow (a highly proliferative tissue) and at 7 d for liver and blood. The canonical, mutational signature of ENU was established by 7 d post-exposure in all four tissues. Interlaboratory analysis of a subset of samples from different tissues and time points demonstrated remarkable reproducibility for both MF and spectrum. These results demonstrate that MF and spectrum can be evaluated successfully by directly sequencing targeted regions of DNA obtained from various tissues, a considerable advancement compared to currently used in vivo gene mutation assays. HIGHLIGHTS: DuplexSeq is an ultra-accurate NGS technology that directly quantifies mutations ENU-dependent mutagenesis was detected 24 h post-exposure in proliferative tissues Multiple tissues exhibited the canonical ENU mutation spectrum 7 d after exposure Results obtained with DuplexSeq were highly concordant between laboratories The Rat-50 Mutagenesis Assay is promising for applications in genetic toxicology


  • Open Access

    Evaluation of the herbicide glyphosate, (aminomethyl)phosphonic acid, and glyphosate‐based formulations for genotoxic activity using in vitro assays

    by Stephanie L. Smith‐Roe, Carol D. Swartz, Asma Rashid, Nicholas C. Christy, Jamie E. Sly, Xiaoqing Chang, Nisha S. Sipes, Keith R. Shockley, Shawn F. Harris, Sandra J. McBride, et al.

    Glyphosate, the most heavily used herbicide world‐wide, is applied to plants in complex formulations that promote absorption. The National Toxicology Program reported in 1992 that glyphosate, administered to rats and mice at doses up to 50,000 ppm in feed for 13 weeks, showed little evidence of toxicity, and no induction of micronuclei was observed in the mice in this study. Subsequently, mechanistic studies of glyphosate and glyphosate‐based formulations (GBFs) that have focused on DNA damage and oxidative stress suggest that glyphosate may have genotoxic potential. However, few of these studies directly compared glyphosate to GBFs, or effects among GBFs. To address these data gaps, we tested glyphosate, glyphosate isopropylamine (IPA), and (aminomethyl)phosphonic acid (AMPA, a microbial metabolite of glyphosate), 9 high‐use agricultural GBFs, 4 residential‐use GBFs, and additional herbicides (metolachlor, mesotrione, and diquat dibromide) present in some of the GBFs in bacterial mutagenicity tests, and in human TK6 cells using a micronucleus assay and a multiplexed DNA damage assay. Our results showed no genotoxicity or notable cytotoxicity for glyphosate or AMPA at concentrations up to 10 mM, while all GBFs and herbicides other than glyphosate were cytotoxic, and some showed genotoxic activity. An in vitro to in vivo extrapolation of results for glyphosate suggests that it is of low toxicological concern for humans. In conclusion, these results demonstrate a lack of genotoxicity for glyphosate, consistent with observations in the NTP in vivo study, and suggest that toxicity associated with GBFs may be related to other components of these formulations.


  • Open Access

    Error-corrected Duplex Sequencing enables direct detection and quantification of mutations in human TK6 cells with remarkable inter-laboratory consistency

    by Eunnara Cho, Carol D. Swartz, Andrew Williams, Miriam Rivas, Leslie Recio, Kristine L. Witt, Elizabeth K. Schmidt, Jeffry Yaplee, Thomas H. Smith, Phu Van, et al.

    Error-corrected Duplex Sequencing (DuplexSeq) enables direct quantification of low-frequency mutations and offers tremendous potential for chemical mutagenicity assessment. We investigated the utility of DuplexSeq to quantify induced mutation frequency (MF) and spectrum in human lymphoblastoid TK6 cells exposed to a prototypical DNA alkylating agent, N -ethyl- N -nitrosourea (ENU). Furthermore, we explored appropriate experimental parameters for this application, and assessed inter-laboratory reproducibility. In two independent experiments in two laboratories, TK6 cells were exposed to ENU (25-200 µM) and DNA was sequenced 48, 72, and 96 h post-exposure. A DuplexSeq mutagenicity panel targeting twenty 2.4-kb regions distributed across the genome was used to sample diverse, genome-representative sequence contexts. A robust increase in MF that was unaffected by time was observed in both laboratories. Concentration-response in the MF from the two laboratories was strongly positively correlated (R 2 =0.95). C:G>T:A, T:A>C:G, T:A>A:T, and T:A>G:C mutations increased in consistent, concentration-dependent manners in both laboratories, with high proportions of C:G>T:A at all time points. The target sites responded similarly between the two laboratories and revealed a higher average MF in intergenic regions. These results, demonstrating remarkable reproducibility across time and laboratory for both MF and spectrum, support the high value of DuplexSeq for characterizing chemical mutagenicity in both research and regulatory evaluation.


  • Response to Letter to the Editor

    by Stephanie L. Smith‐Roe, Keith R. Shockley, John R. Bucher, Kristine L. Witt